Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
Chin Med J (Engl). 2012 Jul;125(14):2636-7.
Imatinib mesylate is a molecular targeted agent for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumor. Although imatinib mesylate is not regarded as an immunosuppressive agent, few studies have also shown that it may impair immune response. In this report, we present a case of transient hepatitis B virus (HBV) reactivation during imatinib mesylate treatment for CML.
甲磺酸伊马替尼是一种治疗慢性髓性白血病（CML）和胃肠道间质瘤的分子靶向药物。虽然甲磺酸伊马替尼不被认为是免疫抑制剂，但也有少数研究表明它可能会损害免疫反应。在本报告中，我们报告了 1 例 CML 患者在接受甲磺酸伊马替尼治疗期间发生短暂性乙型肝炎病毒（HBV）再激活的病例。
Zotero 插件